Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Short term Debt (2016 - 2023)

Arcadia Biosciences (RKDA) has disclosed Short term Debt for 10 consecutive years, with $15000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Short term Debt fell 78.26% year-over-year to $15000.0, compared with a TTM value of $15000.0 through Mar 2023, down 78.26%, and an annual FY2022 reading of $48000.0, down 25.0% over the prior year.
  • Short term Debt was $15000.0 for Q1 2023 at Arcadia Biosciences, down from $48000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $1.1 million in Q4 2020 and bottomed at $12000.0 in Q1 2019.
  • Average Short term Debt over 5 years is $168235.3, with a median of $40000.0 recorded in 2019.
  • The sharpest move saw Short term Debt soared 2650.0% in 2020, then tumbled 94.89% in 2021.
  • Year by year, Short term Debt stood at $40000.0 in 2019, then skyrocketed by 2650.0% to $1.1 million in 2020, then crashed by 94.18% to $64000.0 in 2021, then fell by 25.0% to $48000.0 in 2022, then tumbled by 68.75% to $15000.0 in 2023.
  • Business Quant data shows Short term Debt for RKDA at $15000.0 in Q1 2023, $48000.0 in Q4 2022, and $47000.0 in Q3 2022.